PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
PD-1 Antibody Adjuvant Therapy for Patients With MSI-H Advanced Gastric or Gastroesophageal Junction Cancer After Radical Surgery With D2 Dissection: a Phase II Single-center, Three-arm, Randomized Controlled Clinical Trial
Sponsor: Fudan University
Listed as NCT05468138, this PHASE2 trial focuses on Adjuvant Therapy and Gastric Cancer and remains ongoing. Sponsored by Fudan University, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .